<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795039</url>
  </required_header>
  <id_info>
    <org_study_id>FULV-006-CP1</org_study_id>
    <nct_id>NCT02795039</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects</brief_title>
  <official_title>Open-label, Two-treatment, Single Period, Parallel, Single-dose, Randomized, Fasting, Lab-blinded Bioequivalence Study of Fulvestrant 50 mg/mL Versus Faslodex®, 50 mg/mL, in Healthy, Post-menopausal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence between the test drug product,&#xD;
      fulvestrant Injection, 50 mg/mL, and the Reference Listed Drug, Faslodex® Injection, 50&#xD;
      mg/mL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to establish bioequivalence between sponsor's test product&#xD;
      [fulvestrant Injection, 50 mg/mL (Manufactured for Fresenius Kabi, USA)] and reference listed&#xD;
      drug [Faslodex® Injection, 50 mg/mL, (Distributed by AstraZeneca Pharmaceuticals, USA] after&#xD;
      intramuscular administration of a 250 mg dose (5 mL injection) into the upper outer quadrant&#xD;
      of the right buttock to normal, healthy, nonsmoking post-menopausal female subjects.&#xD;
&#xD;
      The order of receiving the test product (T) or reference listed drug (R) for each subject&#xD;
      during the study will be determined according to a randomization schedule.&#xD;
&#xD;
      Subjects will be allocated with a ratio of 1:1 to both treatment groups (i.e. T and R).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 3, 2017</completion_date>
  <primary_completion_date type="Actual">March 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>0-238 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-238d) of fulvestrant</measure>
    <time_frame>0-238 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC0-28d) of fulvestrant</measure>
    <time_frame>0-28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to the last measurable concentration (AUC0-t)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC0-∞)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life Period (t1/2)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Slope (λz)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual area in percentage (AUC_%Extrap_obs)</measure>
    <time_frame>0-238 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site pain assessment</measure>
    <time_frame>0-8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fulvestrant 50mg/mL (Fresenius Kabi)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mL intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant 50 mg/mL (Faslodex®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mL intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)</description>
    <arm_group_label>Fulvestrant 50mg/mL (Fresenius Kabi)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)</description>
    <arm_group_label>Fulvestrant 50 mg/mL (Faslodex®)</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal, healthy, non smoking post-menopausal female subjects between the ages of 40&#xD;
             and 65 years (inclusive) Note: Postmenopausal is defined as 12 months of spontaneous&#xD;
             amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt;40 mIU/mL. The&#xD;
             amenorrhea should not be due to lactation&#xD;
&#xD;
          -  Body Mass Index (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less&#xD;
             than or equal to 29.9 kg/m2&#xD;
&#xD;
          -  Physical examination, 12-lead electrocardiogram (ECG) and vital signs without any&#xD;
             clinically significant findings&#xD;
&#xD;
          -  Negative for urine drugs of abuse screen, urine nicotine (cotinine) screen, and breath&#xD;
             alcohol screen.&#xD;
&#xD;
          -  Negative for hepatitis B-surface antigen, hepatitis C and Human Immunodeficiency Virus&#xD;
             (HIV)&#xD;
&#xD;
          -  Clinical laboratory values within the acceptable range, unless deemed clinically not&#xD;
             significant by the principal investigator or sub-investigator.&#xD;
&#xD;
          -  Availability of the subject for the entire study period and willingness of the subject&#xD;
             to adhere to protocol requirements as evidenced by signing the Informed Consent Form&#xD;
             (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant gastrointestinal, renal, hepatic, neurologic,&#xD;
             hematologic, endocrine, oncologic, pulmonary, immunologic, musculoskeletal,&#xD;
             psychiatric, or cardiovascular disease or malignancies or any other condition which,&#xD;
             in the opinion of the principal investigator or sub-investigator, would jeopardize the&#xD;
             safety of the subject or impact the validity of the study results.&#xD;
&#xD;
          -  A history of allergic or adverse response(s) to fulvestrant, castor oil, benzyl&#xD;
             alcohol, benzyl benzoate, polysorbate 80, α-tocopherol or any other comparable or&#xD;
             similar products.&#xD;
&#xD;
          -  Smoking or use of tobacco products within 6 months prior to the first dose of study&#xD;
             drug or during the study&#xD;
&#xD;
          -  Positive urine pregnancy test at screening or serum pregnancy test prior to&#xD;
             administration of study drug.&#xD;
&#xD;
          -  History of any bleeding disorders&#xD;
&#xD;
          -  Consumption of alcohol exceeding 10 drinks/ week in the previous 1 year&#xD;
&#xD;
          -  Intolerance to/fear of venipuncture, needles or blood draws&#xD;
&#xD;
          -  Have consumed any products or undergone any procedures mentioned under &quot;restriction&#xD;
             table&quot; in protocol&#xD;
&#xD;
          -  Surgically-induced post menopausal females&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1L4S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioPharma Services Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

